Key result
Each additional medication in older adults is associated with a ~5% higher mortality risk.
Why the study?
Polypharmacy is common in older adults with comorbidities, but its global prevalence, temporal trends, and dose-response associations with adverse health outcomes needed estimation.
Does polypharmacy increase the risk of mortality and hospital admissions in older adults?
Meta-Analysis (n=16,620,414)
Yes
Does polypharmacy increase the risk of mortality and hospital admissions in older adults?
Polypharmacy affects approximately half of older adults globally and is associated with a dose-dependent increase in mortality and hospital admissions.
Answers are grounded in this paper and cite their sources.
Supports medication review in older adults; extends global prevalence estimates and risk associations from observational data.
BACKGROUND: Polypharmacy is common in older adults with comorbidities. This study aims to estimate its global prevalence, temporal trends, and dose-response associations with adverse health outcomes. METHODS: PubMed, Embase, The Cochrane Library, Web of Science and Scopus were searched from inception to June 30, 2025. Random-effects meta-analyses were used to pool prevalence estimates of polypharmacy based on mixed thresholds and relative risks. Study quality was assessed using Hoy's method. Hazard ratios (HRs) from individual studies were synthesised using random-effects dose-response meta-analysis in studies that provided sufficient quantitative exposure information. RESULTS: A total of 545 studies, providing 565 prevalence estimates, were included, comprising 16,620,414 older adults from 56 countries worldwide. The pooled global prevalence of polypharmacy was 50.4% (95% confidence interval [CI]: 48.2-52.7%; 95% prediction interval: 6.8-93.5%). It demonstrated a significant increasing temporal trend in polypharmacy prevalence over calendar years. Compared with non-polypharmacy, polypharmacy was associated with a significantly higher risk of multiple adverse outcomes. Dose-response meta-analyses showed a monotonic increase in risk with each additional medication for mortality (HR: 1.05, 95%CI: 1.03-1.06, P<0.001), emergency (HR: 1.02, 95%CI: 1.02-1.03, P<0.001), and hospital admission (HR: 1.04, 95%CI: 1.02-1.07, P<0.001). Outcome-specific thresholds ranged from 4.55 to 5.46 medications. A pooled estimate of approximately five medications was obtained as a descriptive summary across outcomes. CONCLUSION: Polypharmacy affects approximately half of older adults worldwide and has increased steadily over time. It is associated with an increased risk of multiple adverse health outcomes, with risks increasing progressively as medication burden rises.
No takes yet. Share an insight, caveat, or question.
Tian et al. (2026) conducted a meta-analysis in Polypharmacy (n=16,620,414). Polypharmacy (each additional medication) vs. Non-polypharmacy was evaluated on Mortality (HR 1.05, 95% CI 1.03-1.06, p=<0.001). Polypharmacy affects 50.4% of older adults globally, and each additional medication monotonically increases the risk of mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: